Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis

Administration of daclizumab, a humanized mAb directed against the IL-2Rα chain, strongly reduces brain inflammation in multiple sclerosis patients. Here we show that daclizumab treatment leads to only a mild functional blockade of CD4(+) T cells, the major candidate in multiple sclerosis pathogenes...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bielekova, Bibiana, Catalfamo, Marta, Reichert-Scrivner, Susan, Packer, Amy, Cerna, Magdalena, Waldmann, Thomas A., McFarland, Henry, Henkart, Pierre A., Martin, Roland
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2006
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1458677/
https://ncbi.nlm.nih.gov/pubmed/16585503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0601335103
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars